The main activity of the Section of Pharmacovigilance and Clinical Trials is to collect, analyse and evaluate the undesirable effects from healthcare professionals and patient reports in Slovak Republic and from the EU. Other activities of Pharmacovigilance Department include risk assessment of selected drugs within the Pharmaceutical division of labor between EU agencies and a timely drafting of expert opinions for the assessment of clinical studies in Slovakia.
The main activities of the Pharmacovigilance Department include:
• collecting data, monitoring and analysing of suspected adverse drug reactions,
• assessing the risks associated with using of medicinal products
• assessment of the conditions under which medicinal products may be used
• communication about the risks of medicines with healthcare providers and consumers
• issuing non-periodical journal on risks of medicinal products named ,,Liekové riziko”
